Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 397

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 397
---
 or was a director, executive officer, employee or agent of LB Pharmaceuticals Inc, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of LB Pharmaceuticals Inc. At present, there is no pending litigation or proceeding involving a director or executive officer of LB Pharmaceuticals Inc regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his capacity as such. The underwriters are obligated, under certain circumstances, under the underwriting agreement to be filed as Exhibit 1.1 hereto, to indemnify us and our officers and directors against liabilities under the Securities Act. II-1

Item 15. Recent Sales of Unregistered Securities.

Set forth below is information regarding all unregistered securities issued and options granted by us since January 1, 2022 through the
date of this registration statement:

Issuance of Common Stock

In 2022, we issued 428,571 shares of our common stock to Rivopharm S.A., or Rivopharm, in lieu of cash payment for work performed by a
subsidiary of Rivopharm, pursuant to an oral agreement between us and an affiliate of Rivopharm. For additional information, see “Certain Relationships and Related Party Transactions—Issuance of Common Stock.”

Issuances Pursuant to our Equity Plans

From January 1, 2022 through the date of this registration statement, we have granted options under our 2023 Stock Incentive Plan to
purchase up to an aggregate of 11,849,488 shares (net of expirations, forfeitures and cancellations) of common stock, at a weighted-average price of $1.50 per share, in each case, to our employees, directors and consultants. From January 1,
2022 through the date of this registration statement, no options have been granted under our 2017 Stock Incentive Plan or 2018 Stock Incentive Plan, and no shares of common stock have been issued upon the exercise of options.

Issuances of Warrants

In May
2022, we issued the Series B-1 Warrants to certain accredited investors to purchase 75,